Subscribe & Save!
Subscribe now and save 50% off the cover price of the Indianapolis Monthly magazine.
×

drugs

1217-Opioid-Opener-Illo-web.jpg
Read More

Indiana’s Drug Czar: The Worst Is Yet To Come

Indiana hasn’t reached the peak of the opioid epidemic yet.

Read More

The Unblinding: Has Lilly Solved the Alzheimer’s Puzzle? — An Epilogue

The search continues.

Alzheimer
Read More

The Unblinding: Has Lilly Solved the Alzheimer’s Puzzle?

Statistician Hong Liu-Seifert will emerge from The Cave knowing the outlook for a $90 billion company—what high-level executives are calling a “binary” event that could result in bringing a drug to market by 2018, and windfall profits; or another blow to the field of Alzheimer’s research.

KP01
Read More

Getting Right: The Long, Slow Recovery of Austin, Indiana

Austin has become a mecca for illegal drug use and crime. The problem was painfully highlighted by the HIV outbreak that hit this spring.

Theresa Rohr-Kirchgraber, M.D.
Read More

Survey Says: Indy Top Doctors Answer Burning Questions

“I wish my patients wouldn’t bash the Affordable Care Act while benefiting from it.”

HOT-BUTTON-OPENER2.jpg
Read More

Hot-Button Issues: The Straight Dope

Indianapolis is drawing heroin straight from Mexico and bypassing Chicago altogether—which might account for the high potency.

Read More

The Undercover Files: Narcotics

“I was introduced to an Outlaws biker once when I was buying meth. The guy pulled out a .44 black powder pistol that was almost a foot long and set it on the table to intimidate me.”

meth-oct2005-3.jpg
Read More

IM Crime Files: The Scourge

Editor’s Note: The following originally appeared in the October 2005 “Small Towns” issue and is included among IM’s Best-Ever Crime Stories.

Read More

Life after Zyprexa: the Future of Eli Lilly and Company

“We want high quality of life as long as possible, don’t we?” says Lilly executive Jan Lundberg. “Many of our current diseases are chronic, and they accumulate with age, so there are major demands coming from the aging population.”

Zyprexa
Read More

Side Effects

With thousands of medical success stories and billions in revenue, officials at Lilly are still celebrating the success of Zyprexa. But its troubled path reveals volumes about how difficult bringing even an approved medication to market can turn out to be.

X
X